Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Other Operating Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Operating Expenses for 7 consecutive years, with -$382.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 17.24% to -$382.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$767.1 million, a 65.97% decrease, with the full-year FY2025 number at -$767.1 million, down 65.97% from a year prior.
  • Other Operating Expenses was -$382.5 million for Q4 2025 at Beam Therapeutics, up from -$384.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $219.7 million in Q3 2024 to a low of -$507.4 million in Q4 2023.
  • A 5-year average of -$233.7 million and a median of -$365.5 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 43.56% in 2021, then crashed 275.08% in 2025.
  • Beam Therapeutics' Other Operating Expenses stood at -$1.2 million in 2021, then plummeted by 30688.63% to -$365.5 million in 2022, then tumbled by 38.83% to -$507.4 million in 2023, then rose by 8.91% to -$462.2 million in 2024, then grew by 17.24% to -$382.5 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Other Operating Expenses are -$382.5 million (Q4 2025), -$384.6 million (Q3 2025), and -$462.2 million (Q4 2024).